Seven-year follow-up data demonstrated favorable clinical outcomes and patient satisfaction for Medtronic’s 2-level Prestige LP™ Cervical Disc vs. 2-level anterior cervical discectomy and fusion (ACDF).
The randomized, controlled, investigational device exemption trial included 397 subjects.
Key findings from statistical analysis at seven years show that 2-level Prestige LP Disc patients exhibited:
Greater rates in overall success (78.6%) vs. 2-level ACDF (62.7%)
Greater rates in neurological success (91.6%) vs. 2-level ACDF (82.1%)
Greater success rates in patient-reported outcomes, including Neck Disability Index (87.0%), vs. 2-level ACDF (75.6%)
Lower rates of second surgeries (4.2%) at index levels vs. 2-level ACDF (14.7%)
Similar adverse event profiles to 2-level ACDF
Prestige LP is pending FDA premarket approval for 2-level use, and is the third cervical disc in Medtronic’s portfolio, alongside BRYAN and Prestige ST.
Presently, LDR’s Mobi-C is the only cervical disc approved for 2-level cervical disc replacement in the U.S.
Sources: Medtronic plc, ORTHOWORLD Inc.
Seven-year follow-up data demonstrated favorable clinical outcomes and patient satisfaction for Medtronic's 2-level Prestige LP™ Cervical Disc vs. 2-level anterior cervical discectomy and fusion (ACDF).
The randomized, controlled, investigational device exemption trial included 397 subjects.
Key findings from statistical analysis at seven...
Seven-year follow-up data demonstrated favorable clinical outcomes and patient satisfaction for Medtronic’s 2-level Prestige LP™ Cervical Disc vs. 2-level anterior cervical discectomy and fusion (ACDF).
The randomized, controlled, investigational device exemption trial included 397 subjects.
Key findings from statistical analysis at seven years show that 2-level Prestige LP Disc patients exhibited:
Greater rates in overall success (78.6%) vs. 2-level ACDF (62.7%)
Greater rates in neurological success (91.6%) vs. 2-level ACDF (82.1%)
Greater success rates in patient-reported outcomes, including Neck Disability Index (87.0%), vs. 2-level ACDF (75.6%)
Lower rates of second surgeries (4.2%) at index levels vs. 2-level ACDF (14.7%)
Similar adverse event profiles to 2-level ACDF
Prestige LP is pending FDA premarket approval for 2-level use, and is the third cervical disc in Medtronic’s portfolio, alongside BRYAN and Prestige ST.
Presently, LDR’s Mobi-C is the only cervical disc approved for 2-level cervical disc replacement in the U.S.
Sources: Medtronic plc, ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
